This article is more than 5 years old. Information may no longer be current.

EvokeDx receives CE mark

Issue: July 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EvokeDx for objective assessment of central vision function, including the diagnosis of glaucoma, has received a CE mark, according to a press release from Konan Medical.

The “next-generation” visual evoked potentials and electroretinogram diagnostic platform is now approved in Europe.

EvokeDx’s patented test strategies are designed “to isolate and objectively test various visual pathways and visual functions, with Fourier-transform frequency analysis methods,” the release said.

The platform has FDA 510(k) clearance in the United States.